News • Imaging equipment

CE Mark for Faxitron Path+ Specimen Radiography System

Hologic, Inc. has announced it has CE Mark for the Faxitron Path+ Specimen Radiography System, the latest addition to the company’s growing portfolio of digital specimen radiography solutions.

Hologic's Faxitron Path+ Specimen Radiography System
Source: Hologic

The system features a superior, high-resolution imaging detector which enables pathologists to image a wide range of specimens of varying sizes, including bone, foetal remains and breast tissue directly in the lab. By combining a larger field of view with intuitive, easy-to-use software, the system provides pathologists with accurate results in an efficient manner. Additionally, the clear specimen images produced enable pathologists to satisfy the regulatory demands for De-Calcification End Point testing. Improving workflow within hospitals, clinicians can access the information they need to diagnose and treat their patients sooner.

The Faxitron Path+ system provides up to 10x geometric magnification, enabling imaging of small microcalcifications and ensuring accurate diagnoses. Optimal x-ray exposure settings can be selected regardless of specimen makeup and density to ensure the highest image quality is maintained. These features offer pathologists more versatile imaging options and help to reduce the Turn Around Time (TAT) for reports, meaning patients can receive their diagnoses more quickly.

Recommended article


Article • Breast and skeletal health

AI is proving pivotal in women’s health solutions

Pete Valenti, Hologic’s division president of breast and skeletal health solutions, talks about how AI is driving innovation in breast health technology. Underpinning that evolution more recently has been the acquisition of two organisations – digital specimen radiography specialists Faxitron Bioptics and BioZorb marker manufacturer Focal Therapeutics.

As a world leader in mammography, Hologic has expanded its business over the past several years to make a meaningful and positive impact on breast health at each step of a patient’s journey, from screening to pathology. The Faxitron Path+ system is one of several innovative products that have been added to Hologic’s portfolio of breast health solutions following its acquisition of Faxitron Bioptics, a longstanding leader in digital specimen radiography.

Source: Hologic


Read all latest stories

Related articles


Article • Digital breast tomosynthesis

Transforming breast screening: The role of AI in improving reading workflow

While having more centers adopt digital breast tomosynthesis (DBT) for breast cancer screenings into their practice is a positive change, it also presents some challenges for…


Article • Supplemental imaging

The next breast screening advancement: Contrast-enhanced mammography

With the recent recommendation changes from the European Council in 2022, how radiologists screen for breast cancer is changing. Mammography has long been an essential technology in screening for…


Article • Digital breast tomosynthesis (DBT)

New EU recommendations for breast screening enhance opportunities for early detection

Mammography has been an essential imaging technology for breast cancer detection for decades. As the industry has continued to innovate, one advancement in mammography has particularly changed the…

Related products

Subscribe to Newsletter